Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk

Candel Therapeutics, Inc. (CADL) has disclosed a new risk, in the Debt & Financing category.

The analyst notes that covenants in the RTW Purchase Agreement constrain Candel Therapeutics, Inc.’s ability to incur debt, grant liens, enter into licenses, and fully leverage its intellectual property, which is pledged as collateral. These restrictions may reduce operational and financial flexibility, and any covenant breach could trigger enforcement of security interests and materially damage its financial condition.

He further observes that mandatory payment obligations to the Purchaser will increase cash outflows and may divert resources from operations, potentially forcing asset sales, capital-raising at dilutive terms, or reduced investment. Inability to meet payment or closing conditions could lead to defaults, acceleration of obligations, foreclosure on assets, and broader adverse effects on its business and results of operations.

The average CADL stock price target is $15.33, implying 207.83% upside potential.

To learn more about Candel Therapeutics, Inc.’s risk factors, click here.